Hagens Berman Alerts Investors to Capricor's FDA Review Extension and Ongoing Securities Class Action#USA#San_Francisco#Hagens_Berman#Capricor_Therapeutics#NASDAQ_CAPR
Hagens Berman Alerts Investors to Capricor's FDA Review Extension and Ongoing Securities Class Action
Hagens Berman announces an FDA review extension for Capricor's Deramiocel while investors face a September deadline for a class action lawsuit.
third-news.com
August 28, 2026 at 5:00 PM
Hagens Berman Alerts Investors to Capricor's FDA Review Extension and Ongoing Securities Class Action#USA#San_Francisco#Hagens_Berman#Capricor_Therapeutics#NASDAQ_CAPR
Class Action Suit Against Capricor Therapeutics: Investors Urged to Act#United_States#DJS_Law_Group#Eastchester#Capricor_Therapeutics#NASDAQ_CAPR
Class Action Suit Against Capricor Therapeutics: Investors Urged to Act
Capricor Therapeutics faces a class action lawsuit for alleged securities law violations. Investors are encouraged to contact the DJS Law Group about their rights and recovery options.
third-news.com
September 15, 2025 at 7:51 AM
Class Action Suit Against Capricor Therapeutics: Investors Urged to Act#United_States#DJS_Law_Group#Eastchester#Capricor_Therapeutics#NASDAQ_CAPR
Investors Urged to Act as Pomerantz Law Firm Investigates Capricor Therapeutics Claims#United_States#New_York#Pomerantz_LLP#Capricor_Therapeutics#NASDAQ_CAPR
Investors Urged to Act as Pomerantz Law Firm Investigates Capricor Therapeutics Claims
Pomerantz Law Firm is probing Capricor Therapeutics on behalf of investors due to unresolved allegations of securities fraud and business misconduct.
third-news.com
August 6, 2025 at 2:24 PM
Investors Urged to Act as Pomerantz Law Firm Investigates Capricor Therapeutics Claims#United_States#New_York#Pomerantz_LLP#Capricor_Therapeutics#NASDAQ_CAPR